I cannot directly provide or link to a PDF copy of PDA Technical Report No. 27 (TR 27) Pharmaceutical Package Integrity due to copyright restrictions. PDA reports are proprietary documents protected by intellectual property law.

Defining what constitutes an "integral" package and setting scientific limits for leak rates Test Method Selection:

. It is a foundational guidance document for the pharmaceutical industry, specifically focusing on: Parenteral Drug Association Container Closure Integrity (CCI):

TR 27’s Recommendation: Use deterministic methods whenever feasible; microbial challenge should be used only for validation of deterministic method sensitivity limits.

1. The Concept of "Maximum Allowable Leakage Limit" (MALL)

TR 27 introduced a risk-based concept: not every leak must be detectable. The MALL is the largest leak that still ensures sterility over the product’s shelf life. The report guides you to set a MALL based on:

The report is structured to assist users in developing robust integrity assessment strategies. Major sections include: